Previous 10 | Next 10 |
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jeff...
2024-05-27 01:48:01 ET More on BioRestorative Therapies BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript BioRestorative gains as FDA clears amendment to study on cell therapy candidate Seeking Alpha’s Quant Rating on BioRestorative Therap...
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it receiv...
MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to reach a value of $232.49 billion by 2032 , growing at a CAGR of 13.34% between 2024 and 2032....
2024-05-15 08:11:57 ET More on BioRestorative Therapies BioRestorative gains as FDA clears amendment to study on cell therapy candidate Seeking Alpha’s Quant Rating on BioRestorative Therapies Historical earnings data for BioRestorative Therapies Finan...
2024-05-14 19:08:02 ET BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Conference Call May 14, 2024, 04:30 PM ET Company Participants Stephen Kilmer - Head of Investor Relations Lance Alstodt - President, Chief Executive Officer and Chairman of the Board R...
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today provided an update on its b...
— New therapeutic candidate developed using Company’s patented ThermoStem ® platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss — ...
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRT...
2024-04-30 08:32:26 ET More on BioRestorative Therapies, Inc. BioRestorative gains as FDA clears amendment to study on cell therapy candidate BioRestorative Therapies tumbles after private placement Seeking Alpha’s Quant Rating on BioRestorative Therapies, Inc...
News, Short Squeeze, Breakout and More Instantly...
BioRestorative Therapies Inc Company Name:
BRTX Stock Symbol:
OTCMKTS Market:
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: ...
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem ® licensing opportunities – – Substantive di...
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX ...